PolarityTS (PTE) Reports Q4 Loss of $4.29

PolarityTS (NASDAQ: PTE) reported Q4 EPS of ($4.29), $3.38 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $800 thousand.

Denver Lough, MD, PhD, Chairman & CEO said, "I'm very excited by the progress we made in 2018. We successfully transitioned from a limited market release of our SkinTE product to the beginning of a regional market release. With this transition we have begun to hire a sales force to drive revenue and effectively commercialize SkinTE as we move through 2019. I'm proud of what we have accomplished, but I'm also proud to be part of a team that is focused on delivering the type of technology that can disrupt the current standard of care."

"As we look to 2019, there are a number of milestones that I look forward to, including: the continued commercial rollout of SkinTE in the US; maturation of data that we expect will help drive continued adoption of SkinTE and validation of our platform; an inflection of medical conference presentations by doctors with SkinTE experience to provide further evidence of its efficacy; more clinical data and case studies that show the benefits of SkinTE over the current standard of care, skin grafts; and the market introduction of OsteoTE in the US."

For earnings history and earnings-related data on PolarityTS (PTE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Fort Technology posts 49% revenue rise in first half of 2026
• Boost Run posts Q2 revenue of $31.1M, up 270% year over year